Alexander Olawaiye, MD, presents results from the phase 3 ROSELLA trial, in which relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, with a manageable safety profile.
Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.
Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.
The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.
Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.
Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
Joshua K. Sabari, MD, discusses the design of the phase 1/2 ARROS-1 study, as well as key efficacy data with zidesamtinib in ROS1 fusion–positive NSCLC.
Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.
Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.
TAR-200 was found to be highly effective in treating select patients with bladder cancer whose tumors were previously unresponsive to therapy.
